Welcome to the e-CCO Library!

P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Yarur1, M. Chiorean2, J. Zhang3, W. Reinisch4, S. Vermeire5, J. Panés6, L. Peyrin-Biroulet7, B.E. Sands8, C.H. Cabell3, S.U. Naik3, W.J. Sandborn9

Created: Thursday, 30 January 2020, 10:12 AM
P682: Antibiotic resistome profiles of fecal Escherichia coli isolates in association with Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Siniagina, M.(1);Markelova, M.(1);Boulygina, E.(1);Laikov, A.(1);Khusnutdinova, D.(1);Abdulkhakov, S.(1);Grigoryeva, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P682: Development of anti-ustekinumab antibodies is an independent factor associated to loss of response to ustekinumab therapy in IBD patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Roblin, X.(1)*;Nancey, S.(2);Bastide, L.(3);Veyrard, P.(3);Bischetti, G.(4);Berger, A.E.(5);Barrau, M.(6);Paul, S.(5);
Created: Friday, 14 July 2023, 11:12 AM
P682: GO-CARE: a prospective multi-centre observational study of golimumab effectiveness and quality of life in a real life UC patient population in Italy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Armuzzi1, A. Gasbarrini2, S. Marchi3, S. Saibeni4, V. Germano*5, S. Cercone5, F. Bossa7, A. C. Privitera8

Created: Friday, 22 February 2019, 9:41 AM
P682: Predictors of response to biologics in Ulcerative Colitis: A population-based study from the epi-IIRN
Year: 2022
Source: ECCO'22
Authors: Atia, O.(1); Lujan, R.(1); Greenfeld, S.(2); Kariv, R.(2); Matz, E.(3); Dotan, I.(4); Nevo, D.(5);Turner, D.(1);
Created: Friday, 11 February 2022, 3:56 PM
P682: Risk factors and clinical outcome in IBD patients with melanoma
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Nissen L.H.*1, Pierik M.2, Derikx L.A.A.P.3, de Jong E.4, Kievit W.3, van den Heuvel T.2, van Rosendael A.5, Plasmeijer E.5, Dewint P.6, Nagtegaal I.D.7, Hoentjen F.3, van der Meulen A.5

Created: Wednesday, 20 February 2019, 10:36 AM
P682: Role of laboratory markers in paediatric inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Shentova*, P. Yaneva, M. Baycheva, P. Hadjiiski, D. Kofinova, C. Zhelev

Created: Thursday, 21 February 2019, 9:14 AM
P683 Infliximab, adalimumab and vedolizumab levels are not altered by pregnancy progression in IBD patients and neonatal vedolizumab levels are lower than in mothers: Results from the PICCOLO study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Flanagan1, P.R. GIbson2, O. Rosella3, A. Ross4, S.J. Bell4, The PICCOLO Study

Created: Thursday, 30 January 2020, 10:12 AM
P683: Discontinuation of infliximab treatment: a comparison between IBD patients who retransitioned to originator and those who remained on biosimilar
Year: 2022
Source: ECCO'22
Authors: Meijboom, R.(1);Gardarsdottir, H.(2);Becker, M.(1);Movig, K.(3);Egberts, T.(2);Giezen, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P683: Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Samaan*1, G. Cunningham1, A. G. Tamilarasan1, K. Rawstron2, K. Hawash2, L. Beltran2, I. Koumoutsos1, S. Ray1, J. Mawdsley1, S. Anderson1, J. Sanderson1, Z. Arkir2, P. Irving1

Created: Friday, 22 February 2019, 9:41 AM
P683: Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF-α treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Borruel N.*1, Guillen M.C.2, Salvador F.3, Herrera C.1, Alcover M.M.2, Sulleiro E.4, Robles V.1, Berenguer D.2, Sánchez-Montalvá A.3, Rodríguez V.1, Tomás-Pérez M.2, Molina I.3, Navarro E.1, Iniesta L.2, Fisa R.2, Riera C.2, Casellas F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P683: Maintenance of deep remission in patients with ulcerative colitis treated with thiopurines after withdrawal of the drug: Perspective real-life experience of a single centre
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Mazza*, C. Praticò, M. Salice, A. Calafiore, L. Calandrini, C. Calabrese, M. Campieri, F. Rizzello, P. Gionchetti

Created: Thursday, 21 February 2019, 9:14 AM
P683: Patients with newly diagnosed fistulizing perianal Crohn's disease have a distinct microbial signature
Year: 2021
Source: ECCO'21 Virtual
Authors: Goren, I.(1);Ian, W.(2);Reshef, L.(3);Sharar Fischler, T.(1);Pauker, M.(1);Silverman, J.(4);Dotan, I.(1);Yanai, H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P683: Risk factors for fatigue in IBD patients.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sina, M.(1)*;Djegsi, A.(1);Pemaj, X.(1);Telaku, S.(2);Babameto, A.(1);Prifti, S.(1);
Created: Friday, 14 July 2023, 11:12 AM
P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B.E. Sands1, P.R. Taub2, B.G. Feagan3, A. Armuzzi4, A.O. Damião5, N. Lawendy6, G. Solano7, K. Kwok8, J. Woolcott6, L. Salese6, C. Su6

Created: Thursday, 30 January 2020, 10:12 AM
P684: A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Taylor M.*1, Duggal A.1, Rowley A.1, Foster M.1, Sirohi S.1, Solanke Y.1, Walshe C.1, Webber S.1, Travis S.2, Irving P.3

Created: Wednesday, 20 February 2019, 10:36 AM
P684: Extra intravenous reinduction of ustekinumab on an already shortening interval is an effective optimisation strategy for patients with refractory Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yao, J.(1)*;Liu, T.(1);Min, Z.(1);
Created: Friday, 14 July 2023, 11:12 AM
P684: Increased risk of cardiovascular disease and high risk profiles compatible with metabolic syndrome in patients with Inflammatory Bowel Disease: a cross-sectional analysis of matched cohorts
Year: 2022
Source: ECCO'22
Authors: SleutjesAM, J.(1);Roeters van Lennep, J.E.(2);Kavousi, M.(3);Aribas, E.(3);van der Woude, C.J.(4);de Vries, A.C.(4);
Created: Friday, 11 February 2022, 3:56 PM
P684: Sleep disturbances in IBD patients without sedative therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

G.E. Gilca-Blanariu1,2*, G. Stefanescu1,2, M. Ciocoiu2

Created: Thursday, 21 February 2019, 9:14 AM